3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
7
Prostatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Ovarian Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Moderate Hepatic Impairment
1
Meningioma
1
Healthy Participants
1
Glioma
1
Esophageal Neoplasms
1
Disease Progression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinosarcoma
1
Interventions
Rituximab
27
acalabrutinib
15
ibrutinib
13
Cyclophosphamide
12
Lenalidomide
10
CT-P10
10
zanubrutinib
9
venetoclax
9
Magnetic Resonance Spectroscopy
8
obinutuzumab
7
Specimen Handling
7
Cytarabine
7
Bendamustine Hydrochloride
7
pirtobrutinib
6
fludarabine
6
Biopsy
6
glofitamab
5
fludarabine phosphate
5
Peripheral Blood Stem Cell Transplantation
5
Cyclosporine
5
brexucabtagene autoleucel
4
Whole-Body Irradiation
4
Mycophenolic Acid
4
Vincristine
3
Stem Cell Transplantation
3
Sirolimus
3
Methotrexate
3
Etoposide
3
Doxorubicin
3
Cyclosporins
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
capivasertib
×
90 days
×
Clear all
No trials found.